IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ancient remedies tested in modern fight against scarred lungs
Disease control Not yet recruitingThis study aims to evaluate whether traditional Chinese medicine can help people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. It will follow 1,000 patients for two years to see if the treatment reduces symptom flare-ups, slows disease progression, an…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Stem cell shot tested for scarred lungs
Disease control Not yet recruitingThis is a very early study to check if a new stem cell treatment is safe for people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. It will involve 12 participants who will receive the treatment by IV infusion. The main goal is to see if the treatment c…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Engineered 'Smart Cells' target deadly lung scarring in pioneering trial
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy for people with severe, end-stage idiopathic pulmonary fibrosis (IPF), a fatal lung-scarring disease. Doctors will give patients specially engineered immune cells designed to find and calm the scar tissue in the lungs. The main…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial aims to slow scarring lung disease
Disease control Not yet recruitingThis study is testing whether an experimental drug called BC006 can help control idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 96 people with IPF will receive either BC006 or a placebo for 24 weeks to see if it safely slows the decline in lung functi…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: Dragonboat Biopharmaceutical Company Limited • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New inhaled therapy tested to slow scarring of the lungs
Disease control Not yet recruitingThis study is testing whether inhaling a drug called nintedanib (AP02) can help slow down lung scarring in people with Idiopathic Pulmonary Fibrosis (IPF). About 160 adults with IPF will be randomly assigned to receive one of two doses of the inhaled drug or a placebo (an inactiv…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Head-to-Head battle: new drug challenges standard for deadly lung disease
Disease control Not yet recruitingThis study aims to see if a new drug called LYT-100 (deupirfenidone) works better and is as safe as the current standard drug, pirfenidone, for adults with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 1,100 participants will be randomly assigned to …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC
-
Can video calls help patients breathe easier? new study tests remote coaching for scarred lungs
Symptom relief Not yet recruitingThis study is testing whether a remote coaching program using video calls can help people with idiopathic pulmonary fibrosis (IPF) better manage their own care. It aims to see if this approach improves how patients monitor their symptoms, follow their treatment, and handle flare-…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
Massive study launches to map the journey of a scarring lung disease
Knowledge-focused Not yet recruitingThis study aims to better understand Idiopathic Pulmonary Fibrosis (IPF) by observing over 2800 patients in China. It will collect detailed information on how the disease progresses, what symptoms patients experience, and how it affects their quality of life. The goal is to creat…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC